Global Partnership Leverages AI Technology to Improve Breast Cancer Diagnosis and Treatment

Strategic Insights -

The Breast International Group (BIG) and Paige, a leader in next-generation AI technology, have formed a new partnership to conduct collaborative research aimed at enhancing breast cancer diagnosis, treatment, and patient outcomes. By combining BIG's clinical expertise and comprehensive patient datasets with Paige's advanced AI capabilities, the partnership aims to generate new insights that improve biomarker detection, predict response to treatment, and enable personalized therapy.

Key Takeaways:

  • The partnership will leverage Paige's OmniScreen[TM] AI application, which simulates a panel of 1,600 clinically significant cancer biomarkers within 505 genes by analyzing H&E-stained images, to identify mutation-associated phenotypes in breast cancer.
  • The research will focus on addressing unmet clinical needs in breast cancer, including rare subtypes, and explore additional applications of Paige's technology to standardize the measurement of residual cancer burden and support more effective patient stratification.
  • The collaboration aims to support informed clinical decisions and accelerate the delivery of personalized care for people with breast cancer by embedding AI earlier in diagnostic and research workflows.
  • Paige's AI technology has the potential to reduce unnecessary treatment, improve testing turnaround time, and speed up clinical decision-making, allowing clinicians to focus only on the tests most needed for individualized patient care.
  • BIG's expertise in breast cancer research, combined with Paige's AI capabilities, will strengthen understanding of tumor biology, enhance trial design, and accelerate progress toward more tailored and effective treatments.
  • The partnership reflects a shared mission to improve the lives of people with breast cancer and marks a significant step towards integrating advanced digital pathology tools into BIG's scientific portfolio.

Statistics:

  • 1,600 clinically significant cancer biomarkers within 505 genes will be analyzed by Paige's OmniScreen[TM] AI application.
  • Paige's AI technology has access to millions of digitized pathology slides, clinical reports, and genomic data.
  • 50 research groups from around the world are affiliated with BIG, representing thousands of specialized hospitals, research centers, and world-class breast cancer experts across 70 countries on 6 continents.
  • 30 clinical trials are run or under development under the BIG umbrella at any one time.
  • Paige has developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products.

Sources:

  • BusinessWire: "Paige Partners with Breast International Group to Conduct Collaborative Research on Breast Cancer Diagnosis and Treatment"
  • Paige: "About Paige"
  • Breast International Group: "About BIGagainstbreastcancer.org"
  • BusinessWire: https://www.businesswire.com/news/home/20250610478964/en/